ICD-10-CM Code E85.8

Other amyloidosis

Version 2021 Replaced Code Non-Billable Code

Not Valid for Submission

E85.8 is a "header" nonspecific and non-billable code code, consider using a code with a higher level of specificity for a diagnosis of other amyloidosis. The code is NOT valid for the year 2021 for the submission of HIPAA-covered transactions.

Short Description:Other amyloidosis
Long Description:Other amyloidosis

Consider the following ICD-10 codes with a higher level of specificity:

  • E85.81 - Light chain (AL) amyloidosis
  • E85.82 - Wild-type transthyretin-related (ATTR) amyloidosis
  • E85.89 - Other amyloidosis

Replaced Code

This code was replaced in the 2021 ICD-10 code set with the code(s) listed below. The National Center for Health Statistics (NCHS) has published an update to the ICD-10-CM diagnosis codes which became effective October 1, 2020. This code was replaced for the FY 2021 (October 1, 2020 - September 30, 2021).

  • E85.81 - Light chain (AL) amyloidosis
  • E85.81 - Light chain (AL) amyloidosis
  • E85.82 - Wild-type transthyretin-related (ATTR) amyloidosis
  • E85.82 - Wild-type transthyretin-related (ATTR) amyloidosis
  • E85.89 - Other amyloidosis
  • E85.89 - Other amyloidosis

Clinical Information

  • IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS-. a nonproliferative disorder of the plasma cell characterized by excessive production and misfolding of immunoglobulin light chains that form insoluble amyloid fibrils see amyloid deposits in various tissues. clinical features include liver failure; multiple myeloma; nephrotic syndrome; restrictive cardiomyopathy and neuropathies.
  • AMYLOIDOSIS-. a group of sporadic familial and/or inherited degenerative and infectious disease processes linked by the common theme of abnormal protein folding and deposition of amyloid. as the amyloid deposits enlarge they displace normal tissue structures causing disruption of function. various signs and symptoms depend on the location and size of the deposits.
  • AMYLOIDOSIS FAMILIAL-. diseases in which there is a familial pattern of amyloidosis.
  • AMYLOID NEUROPATHIES FAMILIAL-. inherited disorders of the peripheral nervous system associated with the deposition of amyloid in nerve tissue. the different clinical types based on symptoms correspond to the presence of a variety of mutations in several different proteins including transthyretin prealbumin; apolipoprotein a i; and gelsolin.
  • CEREBRAL AMYLOID ANGIOPATHY FAMILIAL-. a familial disorder marked by amyloid deposits in the walls of small and medium sized blood vessels of cerebral cortex and meninges.

Code Classification

  • Endocrine, nutritional and metabolic diseases (E00–E90)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021

Information for Patients


Amyloidosis occurs when abnormal proteins called amyloids build up and form deposits. The deposits can collect in organs such as the kidney and heart. This can cause the organs to become stiff and unable to work the way they should.

There are three main types of amyloidosis:

  • Primary - with no known cause
  • Secondary - caused by another disease, including some types of cancer
  • Familial - passed down through genes

Symptoms can vary, depending upon which organs are affected. Treatment depends on the type of amyloidosis you have. The goal is to help with symptoms and limit the production of proteins. If another disease is the cause, it needs to be treated.

  • Cardiac amyloidosis (Medical Encyclopedia)
  • Hereditary amyloidosis (Medical Encyclopedia)
  • Primary amyloidosis (Medical Encyclopedia)
  • Secondary systemic amyloidosis (Medical Encyclopedia)

[Learn More]